DVAX vs. ALKS, LGND, BCRX, FOLD, CLDX, INVA, MNKD, NVAX, OPK, and GERN
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.
Dynavax Technologies vs. Its Competitors
Dynavax Technologies (NASDAQ:DVAX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.
Dynavax Technologies has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
In the previous week, Alkermes had 1 more articles in the media than Dynavax Technologies. MarketBeat recorded 3 mentions for Alkermes and 2 mentions for Dynavax Technologies. Alkermes' average media sentiment score of 1.09 beat Dynavax Technologies' score of 0.93 indicating that Alkermes is being referred to more favorably in the news media.
Alkermes has a net margin of 23.30% compared to Dynavax Technologies' net margin of -20.39%. Alkermes' return on equity of 27.52% beat Dynavax Technologies' return on equity.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Dynavax Technologies currently has a consensus target price of $24.00, indicating a potential upside of 141.94%. Alkermes has a consensus target price of $40.00, indicating a potential upside of 39.81%. Given Dynavax Technologies' higher possible upside, equities analysts clearly believe Dynavax Technologies is more favorable than Alkermes.
Alkermes has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Summary
Alkermes beats Dynavax Technologies on 13 of the 17 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 7/1/2025 by MarketBeat.com Staff
